Detecting Cancer Patents (Class 435/6.14)
-
Patent number: 10489904Abstract: The subject disclosure presents systems and computer-implemented methods for assessing a risk of cancer recurrence in a patient based on a holistic integration of large amounts of prognostic information for said patient into a single comparative prognostic dataset. A risk classification system may be trained using the large amounts of information from a cohort of training slides from several patients, along with survival data for said patients. For example, a machine-learning-based binary classifier in the risk classification system may be trained using a set of granular image features computed from a plurality of slides corresponding to several cancer patients whose survival information is known and input into the system. The trained classifier may be used to classify image features from one or more test patients into a low-risk or high-risk group.Type: GrantFiled: December 9, 2016Date of Patent: November 26, 2019Assignees: Ventana Medical Systems, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael Barnes, Srinivas Chukka, David Knowles
-
Patent number: 10472679Abstract: Measurement of mRNAs in urinary cells offers a noninvasive means of diagnosing fibrosis in kidneys. One aspect of the invention is a method that includes: (a) measuring quantities of vimentin mRNA, NKCC2 mRNA, and E-cadherin mRNA in a test sample of cells obtained from urine; and (b) determining whether the vimentin mRNA quantity is higher, the NKCC2 mRNA quantity is lower, or the E-cadherin mRNA is higher than in healthy urinary cells; and thereby detecting that the sample is a fibrotic kidney sample. Step (a) can also include measuring the quantity of RNA expressed by a housekeeping gene (e.g., 18S rRNA). The quantities of vimentin mRNA, NKCC2 mRNA, and E-cadherin mRNA can be normalized against the quantity of housekeeping gene RNA.Type: GrantFiled: May 15, 2013Date of Patent: November 12, 2019Assignee: Cornell UniversityInventors: Manikkam Suthanthiran, Joseph E. Schwartz, Ruchuang Ding, Thangamani Muthukumar
-
Patent number: 10472659Abstract: The present disclosure relates to methods and compositions for ATP regeneration system for use in conjunction with the strand invasion step of an isothermal nucleic acid amplification which uses recombinases that utilize ATP as an energy source.Type: GrantFiled: April 12, 2017Date of Patent: November 12, 2019Assignee: GENEFORM TECHNOLOGIES LIMITEDInventor: Mark Jay Hoser
-
Patent number: 10473662Abstract: Compositions and methods useful for diagnosis and prognosis of cancer are provided. More particularly, methods for detecting breast or prostate cancer protein or nucleic acid biomarkers consisting of iron homeostasis biomarkers in a biological sample obtained from a subject are provided.Type: GrantFiled: September 21, 2016Date of Patent: November 12, 2019Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCESInventors: Frank M. Torti, Suzy V. Torti, Lance Miller
-
Patent number: 10474281Abstract: A touch display driving integrated circuit (IC) includes a touch driver IC configured to be connected to touch electrodes through touch sensing lines and provide a sensing signal to first touch sensing lines among the touch sensing lines in a touch period. The touch driver IC is further configured to apply a common voltage to second touch sensing lines among the touch sensing lines and apply a voltage different from the common voltage to third touch sensing lines different from the second touch sensing lines in a display period.Type: GrantFiled: February 7, 2017Date of Patent: November 12, 2019Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Haewoon Park, Seung-Hoon Baek, Jaehun Jeong, Hyeokchul Kwon
-
Patent number: 10451625Abstract: Method and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of a series of biomarkers, as compared to a control sample lacking cancer. The expression of the biomarker either increases or decreases in samples from subjects with cancer, as compared to the expression level in subjects without cancer. The sample is optimally an ocular sample, such as an isolated tear sample or ocular wash, but can also be from saliva, or other bodily fluid. Kits can include a collection tube and protease inhibitors or protein stabilizers.Type: GrantFiled: October 9, 2015Date of Patent: October 22, 2019Assignee: Ascendant Diagnostics, LLCInventors: Anna Daily, Lindsay Rutherford
-
Patent number: 10449252Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.Type: GrantFiled: April 16, 2013Date of Patent: October 22, 2019Assignees: National University Corporation Chiba University, National University Corporation Yamaguchi UniversityInventors: Toshinori Nakayama, Akihiro Hasegawa, Mutsunori Shirai
-
Patent number: 10443086Abstract: The present invention relates generally to the use of a class of surfactants for emulsion and droplet polymerase chain reaction (“PCR”) mixtures. The class of surfactants consists of those having the chemical formula R—(OCH2CH2)n—OH, wherein R is an alkyl group consisting of 12 to 18 carbons and n is 2 to 25. The present invention also relates to methods, devices, systems, and kits incorporating the above-described class of surfactants.Type: GrantFiled: December 30, 2014Date of Patent: October 15, 2019Assignee: University of Maryland, College ParkInventors: Ian M. White, Kunal Pandit, Srinivasa Raghavan
-
Patent number: 10443057Abstract: This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.Type: GrantFiled: July 22, 2015Date of Patent: October 15, 2019Assignee: Biomics Biotechnologies, Co., Ltd.Inventors: York Yuan Yuan Zhu, Tiejun Li
-
Patent number: 10428377Abstract: Methods are provided for detecting low copy nucleic acids of interest in a sample. In one method, a sample comprising a nucleic acid of interest is aliquotted into a plurality of reaction mixtures, at least two of which are single-copy reaction mixtures. The reaction mixtures are subjected to one or more amplification reactions while flowing through a channel of a microfluidic device. At least one of the reaction mixtures is formulated in an aqueous phase of an emulsion comprising aqueous droplets suspended in an immiscible liquid. The nucleic acid of interest is present as a single copy in at least one aqueous droplet of the aqueous phase prior to performing the amplification reaction(s). Amplification is performed on the reaction mixture when it is formulated in the emulsion. The nucleic acid is continuously flowed during a plurality of steps of the method.Type: GrantFiled: April 14, 2014Date of Patent: October 1, 2019Assignee: CALIPER LIFE SCIENCES, INC.Inventors: Michael R. Knapp, Jill M. Baker, Andrea W. Chow, Anne R. Kopf-Sill, Michael Spaid
-
Patent number: 10428390Abstract: The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.Type: GrantFiled: September 20, 2017Date of Patent: October 1, 2019Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 10420840Abstract: The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.Type: GrantFiled: April 10, 2015Date of Patent: September 24, 2019Assignee: RLL, LLCInventors: Robert J. Hickey, Linda H. Malkas
-
Patent number: 10417225Abstract: An automatic service monitor in an information-technology environment performs regular search queries against generated machine data to derive performance measurements. The information technology environment is defined in terms of services provided by entities, and the performance measurements are defined as key performance indicators (KPIs) of the services. Generated machine data used by the search queries pertain to the entities performing the service. Definitional information for the services, entities, and KPIs is administered by a user to control the operation of the service monitor. Various aspects of such definitional information as well as related performance measurement information may be presented in a unified console display tailored to, and organized around, a particular entity. The console display may serve as a central launch point by supporting user interaction to navigate to other specialized monitoring interfaces.Type: GrantFiled: March 31, 2016Date of Patent: September 17, 2019Assignee: Splunk Inc.Inventors: Nicholas Matthew Tankersley, Fang I Hsiao, Arun Ramani
-
Patent number: 10416164Abstract: The present disclosure relates generally to determining the risk of developing breast cancer. In particular, the present disclosure provides materials and methods for determining whether a subject diagnosed with a non-cancerous breast tumor will develop cancer based on expression of multiple oncogenic biomarkers in the non-cancerous breast tumor. The present disclosure also provides a cancer risk score to determine whether a subject has low risk, intermediate risk, or high risk of developing cancer, thereby permitting selection of appropriate therapies to treat the subject. The present disclosure addresses the need for improved diagnostic assessment of early hyperplastic lesions, the presence of which in a subject is a significant indicator that a subject will eventually develop invasive breast cancer.Type: GrantFiled: February 7, 2018Date of Patent: September 17, 2019Assignee: SILBIOTECH, INC.Inventor: Indira Poola
-
Patent number: 10414817Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: July 2, 2018Date of Patent: September 17, 2019Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Patent number: 10415092Abstract: Compositions that are used in nucleic acid amplification in vitro are disclosed, which include a target specific universal (TSU) promoter primer or promoter provider oligonucleotide that includes a target specific (TS) sequence that hybridizes specifically to a target sequence that is amplified and a universal (U) sequence that is introduced into the sequence that is amplified, by using a primer for the universal sequence. Methods of nucleic acid amplification in vitro are disclosed that use one or more TSU oligonucleotides to attached a U sequence to a target nucleic acid in a target capture step and then use a primer for a U sequence in subsequent amplification steps performed in substantially isothermal conditions to make amplification products that contain a U sequence that indicates the presence of the target nucleic acid in a sample.Type: GrantFiled: January 27, 2017Date of Patent: September 17, 2019Assignee: GEN-PROBE INCORPORATEDInventors: Steven T. Brentano, Dmitry Lyakhov, James D. Carlson, Norman C. Nelson, Lyle J. Arnold, Michael M. Becker
-
Patent number: 10392667Abstract: The present invention features methods, devices, and kits for predicting the sensitivity of a patient to a compound or medical treatment, such as fulvestrant.Type: GrantFiled: February 5, 2014Date of Patent: August 27, 2019Assignee: Medical Prognosis Institute A/SInventor: Steen Knudsen
-
Patent number: 10383953Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.Type: GrantFiled: March 20, 2015Date of Patent: August 20, 2019Assignee: GENZYME CORPORATIONInventors: Catherine O'Riordan, Matthew Adamowicz
-
Patent number: 10376569Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: December 5, 2018Date of Patent: August 13, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10381105Abstract: Systems and methods disclosed for recommending beauty products for a subject by using a DNA sequencer to generate genetic information; aggregating genetic information, beauty trend data, and cosmetic product response from a patient population; deep learning with a computer to generate at least one computer implemented classifier that predicts matching beauty products based on the genetic information, beauty trend data, and cosmetic product response from a patient population; and recommending one or more beauty products for the subject.Type: GrantFiled: January 24, 2017Date of Patent: August 13, 2019Assignee: BaoInventor: Bao Tran
-
Patent number: 10380499Abstract: Summarizing, the application relates to a machine-learning system for adaptively changing a matching threshold of a biometric system. The machine-learning system comprises a batch aggregator device operable to receive input data from the biometric system via a communication interface and to aggregate a batch of at least some of the received input data. The machine-learning system further comprises a learning expert device operable to compute a new suggestion for a matching threshold value of the biometric system based on the aggregated batch. Finally, the machine-learning system comprises an output device operable to output the computed new suggestion for the matching threshold of the biometric system via the communication interface.Type: GrantFiled: August 26, 2015Date of Patent: August 13, 2019Assignee: Accenture Global Services LimitedInventors: Jarkko Ylipaavalniemi, Thomas Jean Georges M. Moretti, Alastair R. Partington
-
Patent number: 10370719Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine and isolating corresponding mRNA in order to diagnose and treat acute kidney injury (AKI). In particular, certain embodiments relate to the method of capturing EMV from urine applied to a filter device that is capable of capturing EMV. Nucleic acids such as mRNA can be isolated from the EMV using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of IBD.Type: GrantFiled: November 12, 2015Date of Patent: August 6, 2019Assignees: Hitachi Chemical Co., Ltd., Hitachi Chemical Co. America, Ltd., The Regents of the University of CaliforniaInventors: Satish P. RamachandraRao, Ravindra Lall Mehta, Masato Mitsuhashi, Taku Murakami
-
Patent number: 10371703Abstract: The present disclosure relates to monoclonal anti-LINE-1 ORF2 protein endonuclease domain antibody, and fragments and derivatives that bind the LINE-1 ORF2 protein endonuclease domain and inhibit its activity.Type: GrantFiled: November 17, 2015Date of Patent: August 6, 2019Inventors: Victoria Perepelitsa Belancio, Mark Sokolowski
-
Patent number: 10363296Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: December 7, 2018Date of Patent: July 30, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Colette Song
-
Patent number: 10364277Abstract: The invention relates generally to the field of autoimmunity. More specifically, the invention relates to compositions and methods for the diagnosis, prevention, and treatment of human leukocyte antigen (HLA)-associated autoimmune diseases, and in particular HLA-B27-associated autoimmune diseases.Type: GrantFiled: June 27, 2014Date of Patent: July 30, 2019Assignee: NEWSOUTH INNOVATIONS PTY LIMITEDInventors: Denis Wakefield, Helder Marcal
-
Patent number: 10365266Abstract: The disclosed invention includes methods and kits for the removal of white blood cells from samples of immunomagnetically enriched rare cells by treating the sample with a leukocyte marker conjugated to a hapten which adheres to the white blood cells and treating the resulting product with a second medium that adheres to the hapten of the white blood cells that are labeled with the leukocyte marker conjugated to hapten and removing the labeled white blood cells.Type: GrantFiled: October 11, 2017Date of Patent: July 30, 2019Assignee: Menarini Silicon Biosystems, Inc.Inventors: Galla Chandra Rao, Brad Foulk, Denis Smirnov, Karl Nielsen
-
Patent number: 10351844Abstract: Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.Type: GrantFiled: August 27, 2015Date of Patent: July 16, 2019Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
-
Patent number: 10337057Abstract: A system for performing quality control for nucleic acid sample sequencing is disclosed. The system comprises a set of solid supports, each solid support having attached thereto a plurality of nucleic acid sequences, wherein the set comprises plural groups of solid supports and each group contains solid supports having the same nucleic acid sequences attached thereto. The nucleic acid sequences of each group differ from each other. The nucleic acid sequences are synthetically derived, and the nucleic acids sequences are designed such that the nucleic acid sequences produce a predefined pattern of detectable signals during a sequencing run. A method of preparing a quality control for performing nucleic acid sample sequencing, a method of validating a nucleic acid sequencing instrument during a nucleic acid sequencing experiment, and a method of processing nucleic acid sequencing data during a nucleic acid sequencing experiment are also disclosed.Type: GrantFiled: September 17, 2015Date of Patent: July 2, 2019Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Min-Yi Shen, Douglas Greiner
-
Patent number: 10337058Abstract: A system for performing quality control for nucleic acid sample sequencing is disclosed. The system comprises a set of solid supports, each solid support having attached thereto a plurality of nucleic acid sequences, wherein the set comprises plural groups of solid supports and each group contains solid supports having the same nucleic acid sequences attached thereto. The nucleic acid sequences of each group differ from each other. The nucleic acid sequences are synthetically derived, and the nucleic acids sequences are designed such that the nucleic acid sequences produce a predefined pattern of detectable signals during a sequencing run. A method of preparing a quality control for performing nucleic acid sample sequencing, a method of validating a nucleic acid sequencing instrument during a nucleic acid sequencing experiment, and a method of processing nucleic acid sequencing data during a nucleic acid sequencing experiment are also disclosed.Type: GrantFiled: September 17, 2015Date of Patent: July 2, 2019Assignee: LIFE TECH NOLOGIES CORPORATIONInventors: Min-Yi Shen, Douglas Greiner
-
Patent number: 10337002Abstract: The present invention discloses a set of human microRNAs, or a primary transcript for such microRNAs, or a precursor of such microRNAs, or a mimic of such microRNAs or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening microRNAs and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes.Type: GrantFiled: December 21, 2012Date of Patent: July 2, 2019Assignee: INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY—ICGEBInventors: Mauro Giacca, Serena Zacchigna, Miguel Luis Cunha Mano, Ana Sofia Bregieiro Eulalio
-
Patent number: 10329622Abstract: Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B).Type: GrantFiled: March 6, 2014Date of Patent: June 25, 2019Assignee: CepheidInventors: Leena McCann, Stacey Ellen Wallace, Edwin Wei-Lung Lai, Russell Higuchi
-
Patent number: 10330906Abstract: Advantageous instruments, assemblies and methods are provided for undertaking imaging techniques (e.g., microscopic imaging techniques). The present disclosure provides improved imaging techniques, equipment and systems. More particularly, the present disclosure provides advantageous microscopy/imaging assemblies with rapid sample auto-focusing (e.g., microscopy/imaging assemblies having instant focusing for rapid sample imaging with auto-focusing). The present disclosure provides for high-throughput whole slide imaging with instant focal plane detection. A whole slide imaging platform/assembly that uses instant focusing systems/methods for high-speed sample autofocusing is provided. Such exemplary platforms/assemblies can be used for digital pathology or the like, and can provide improved, faster and cheaper diagnosis/prognosis of ailments/diseases.Type: GrantFiled: July 27, 2016Date of Patent: June 25, 2019Assignee: University of ConnecticutInventor: Guoan Zheng
-
Patent number: 10324095Abstract: A method of predicting the risk of developing osteoarthritis (OA) comprising: (a) measuring the nuclear cellular level of prohibitin (PHB-1) in nucleated cells present in a blood sample from a subject having or suspected of having OA; and (b) comparing said nuclear cellular level to that corresponding to a control sample; and (c) identifying the subject as being at risk of developing OA when the nuclear cellular level of said PHB-1 in said blood sample is higher than in the control sample; and a composition for determining the risk of developing osteoarthritis (OA), said composition comprising: a cell sample from a subject; and a non-naturally occurring molecule for detecting nuclear accumulation of PHB1.Type: GrantFiled: May 19, 2016Date of Patent: June 18, 2019Assignee: VALORISATION HSJ, LIMITED PARTNERSHIPInventor: Alain Moreau
-
Patent number: 10314899Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: December 7, 2018Date of Patent: June 11, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Colette Song
-
Patent number: 10309959Abstract: Methods, systems, compositions and kits are described for detecting cleaved glycans from a glycoconjugate. After labeling the glycan with a nucleic acid charged oligomer described herein, the labeled glycans can be separated under the influence of an electric field or based on their detectable tag and identified.Type: GrantFiled: December 3, 2015Date of Patent: June 4, 2019Assignee: Life Technologies CorporationInventors: James Stray, Shaheer H. Khan
-
Patent number: 10311569Abstract: Systems, methods, devices, and apparatus for detecting sample defects in blood samples processed in automated processing systems are described herein. One aspect describes an automated blood sample processing apparatus having a pre-analytic specimen integrity monitoring device. Another aspect describes devices, systems, and methods for identifying blood components and properties in blood samples. Further aspects relate to systems and methods for setting reference ranges for sample defects and interference in blood samples. Additionally, devices, systems, and methods for identifying defective samples are described.Type: GrantFiled: December 31, 2015Date of Patent: June 4, 2019Assignee: Cerner Innovation, Inc.Inventors: Sameer Bhatia, Anton F. Flieg, Jr., Joseph Eugene Rose, Stephen Ward
-
Patent number: 10308929Abstract: This invention pertains to a method of preparing biological material from a biological sample selected from the group consisting of blood and sputum samples. The method includes the step of altering at least one constitutive characteristic of the biological sample in the presence of a capturing scaffold by adding a lysis buffer containing a solubilising agent and a detergent to the biological sample, for simultaneously inhibiting coagulation of the biological sample; lysing the biological sample to release the biological material from the biological sample, thus making the biological material available; and capturing at least one fraction of the biological material on the capturing scaffold.Type: GrantFiled: September 6, 2012Date of Patent: June 4, 2019Assignee: North-West UniversityInventors: Anne Frederica Grobler, Oksana Levanets
-
Patent number: 10280399Abstract: A method for differentiation of neural stem cells, neurons and GABAergic neurons from mesenchymal stem cells includes culturing the mesenchymal stem cells in a medium containing SB431542, Noggin and LDN193189. By this method, the mesenchymal stem cells are differentiated into neural stem cells, neurons and GABAergic neurons at a high transformation rate without gene manipulation.Type: GrantFiled: December 1, 2016Date of Patent: May 7, 2019Assignee: SNU R&DB FOUNDATIONInventors: Mi Sook Chang, Ji Hye Park
-
Patent number: 10274488Abstract: Aluminum coated glass slides provide a novel glycan array platform. Specifically, aluminum coated glass slides increase sensitivity of fluorescent based assay methods. Additionally, aluminum coated glass slides allows for mass spectroscopic analysis of carbohydrates and provide a platform for examining activity of cellulases. The unique properties of ACG slides include: 1) the metal oxide layer on the surface can be activated for grafting organic compounds such as modified oligosaccharides; 2) the surface remains electrically conductive, and the grafted oligosaccharides can be simultaneously characterized by mass spectrometry and carbohydrate-binding assay; and 3) the slides are more sensitive than transparent glass slides in binding analysis.Type: GrantFiled: February 18, 2014Date of Patent: April 30, 2019Assignee: ACADEMIA SINICAInventors: Chi-Huey Wong, Chung-Yi Wu, Susan Y. Tseng
-
Patent number: 10274497Abstract: An aptamer specific to ovarian cancer and a detection method for ovarian cancer are provided. The aptamer includes a following nucleotide sequence: 5?-ncaaannncnnnnanncnnnnnnnnnnngaannnannngg-3?, wherein n is a nucleotide independently selected from “a,” “t,” “c,” and “g.Type: GrantFiled: February 6, 2017Date of Patent: April 30, 2019Assignee: National Tsing Hua UniversityInventors: Gwo-Bin Lee, Lien-Yu Hung, Chih-Hung Wang, Chien-Yu Fu, Wen-Bin Lee
-
Patent number: 10267808Abstract: Methods and systems are provided for creating molecular barcodes or indicia for cellular constituents within single cells and for resolving such barcodes or indicia with super resolution technologies such as super resolution microscopy. By this approach, numerous molecular species that can be measured simultaneously in single cells. It has been demonstrated that multiple mRNA transcripts can be labeled with a spatially ordered sequence of fluorophores, and that barcode can be resolved. The methods and systems can be used for genome-wide transcriptional profiling in individual cells by super-resolution barcoding and suggest a general strategy to bring large-scale-omics approach into single cells.Type: GrantFiled: March 8, 2011Date of Patent: April 23, 2019Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGYInventor: Long Cai
-
Patent number: 10260108Abstract: A method is provided for selecting a subject diagnosed with cancer as a candidate for treatment with a PARP1 inhibitor, or both a PARP1 inhibitor and a chemotherapeutic agent such as an alkylating agent. The method includes detecting the presence or absence of a mutation in a non-coding region of a PARP1 gene, wherein the presence of a mutation in the PARP1 gene indicates that the cancer can be treated with the PARP1 inhibitor, optionally in conjunction with the chemotherapeutic agent. In a specific, non-limiting example, the PARP1 inhibitor is verliparib (ABT-888).Type: GrantFiled: October 30, 2015Date of Patent: April 16, 2019Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Hussein A. Tawbi, Petr Pancoska, Panagiotis Benos, Marjorie Romkes, Andrew J. Sedgewick, Irina Abecassis
-
Patent number: 10260102Abstract: The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.Type: GrantFiled: October 7, 2014Date of Patent: April 16, 2019Assignee: Roche Molecular Systems, Inc.Inventors: Xiaoju Max Ma, Chitra Manohar, Alison Tsan
-
Patent number: 10260064Abstract: A method of directed evolution screening includes selecting a protein expression platform for an evolution target, expressing a key rupture gene configured to trigger droplet rupture, developing gene regulatory circuits to control expression of the key rupture gene as a function of performance of the evolution target, encapsulating expression components in droplets, and triggering droplet rupture by expressing a rupture agent from the key rupture gene.Type: GrantFiled: March 26, 2015Date of Patent: April 16, 2019Assignee: The Johns Hopkins UniversityInventors: David K. Karig, Joshua T. Wolfe
-
Patent number: 10254283Abstract: The methods of the present invention, relate to the surprising determination that the level of phosphorylation of position 406 (e.g., a serine residue) of human eukaryotic initiation factor 4B (eIF4B), or a corresponding phosphorylatable amino acid of an ortholog thereof, serves as a biomarker for MELK enzymatic (e.g., kinase) and/or oncogenic activity. The methods of the present invention further relate to the surprising determination that the level of phosphorylation of position 3 (e.g., a threonine residue) and/or position 10 (e.g., a serine residue) and/or position 11 (e.g., a threonine residue) of human Histone M3, or a corresponding phosphorylatable amino acid of an ortholog thereof, also serves as a biomarker for MELK enzymatic (e.g., kinase) and/or oncogenic activity.Type: GrantFiled: November 12, 2014Date of Patent: April 9, 2019Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Jean Zhao, Yubao Wang
-
Patent number: 10246749Abstract: The invention relates to a method of diagnosing breast cancer and to the use of biomarkers for the detection and diagnosis of breast cancer.Type: GrantFiled: March 20, 2016Date of Patent: April 2, 2019Assignee: Albert-Ludwigs-Universitaet FreiburgInventors: Elmar Stickeler, Thalia Erbes, Markus Jaeger
-
Patent number: 10249384Abstract: The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treatment regime. The methods may also be used to evaluate protein and/or metabolite levels that correlate with such clinical conditions. The methods are also of use to ascertain the probability outcome for a patient's particular prognosis.Type: GrantFiled: May 27, 2016Date of Patent: April 2, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: John Zachary Sanborn, David Haussler
-
Patent number: 10240194Abstract: Methods of obtaining sequence information about target polynucleotide having a predefined sequence are disclosed. The methods include sequencing by ligation and sequencing by polymerase.Type: GrantFiled: May 13, 2011Date of Patent: March 26, 2019Assignee: Gen9, Inc.Inventors: Joseph Jacobson, Daniel Schindler
-
Patent number: 10240204Abstract: The invention generally relates to methods for assessing the health of a tissue by characterizing circulating nucleic acids in a biological sample. According to certain embodiments, methods for assessing the health of a tissue include the steps of detecting a sample level of RNA in a biological sample, comparing the sample level of RNA to a reference level of RNA specific to the tissue, determining whether a difference exists between the sample level and the reference level, and characterizing the tissue as abnormal if a difference is detected.Type: GrantFiled: December 13, 2016Date of Patent: March 26, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lian Chye Winston Koh, Stephen R. Quake, Hei-Mun Christina Fan, Wenying Pan
-
Patent number: 10242087Abstract: A data manager determines an appropriate number of clusters for continuous data using unsupervised learning. The data manager selects an appropriate number of clusters based on at least one temporal stability measure between continuous data from at least two time intervals.Type: GrantFiled: May 12, 2017Date of Patent: March 26, 2019Assignee: International Business Machines CorporationInventors: Omri Soceanu, Lev Greenberg, Allon Adir